Quick answer
For most conditions, the best time to consider stem cell therapy is the early or moderate stage, while enough healthy cartilage, nerve cells or tissue remains for repair signals to act on. Late-stage disease is not automatically excluded, but expected gains are smaller and the goal shifts from recovery to stabilising function and quality of life. A specialist decides after reviewing your records and scans.
Key takeaways
- Timing depends on your stage on a clinical scale, not on how long you have been unwell.
- Early or moderate stage is the usual target, because repair signals need healthy tissue to act on.
- No trial has proven an ideal window for most conditions, and several large trials missed their main goals.
- Late stage can still be assessed, but goals shift to slowing decline and easing symptoms, and safety review is stricter.
- Never stop prescribed treatment to wait. Get your scores, scans and a specialist opinion first.
What "early", "middle" and "late" stage actually mean
Stage is not how long you have had a condition. It is how much function and healthy tissue you still have, measured on a clinical scale that your doctor can score from an examination, scan or test.
- Early stage: mild or occasional symptoms, daily activities mostly independent, structures still largely intact on imaging.
- Middle stage: symptoms limit some activities, and tests show clear but partial damage.
- Late stage: major loss of function, dependence on help or aids, and scans showing advanced structural damage.
Different conditions use different scales, so “early” has a precise meaning only inside one disease:
| Condition | Common staging scale | What it measures |
|---|---|---|
| Knee osteoarthritis | Kellgren-Lawrence grade (I to IV) | Cartilage loss and joint space on X-ray |
| Parkinson’s disease | Hoehn and Yahr stage (1 to 5) | Spread of movement symptoms and balance |
| Multiple sclerosis | EDSS (0 to 10) | Disability level and walking ability |
| ALS | ALSFRS-R (0 to 48) | Function in speech, swallowing, limbs and breathing |
| Spinal cord injury | ASIA impairment scale (A to E) | Completeness of the injury |
| Cerebral palsy | GMFCS (levels I to V) | Gross motor ability |
| Avascular necrosis | ARCO or Ficat stages | Bone collapse on MRI and X-ray |
Ask your doctor which scale applies to you and what your current score is. That number, not the calendar, is what matters for timing.
Why timing matters: repair needs something left to repair
Stem cells, especially mesenchymal stem cells, work mainly by sending repair and anti-inflammatory signals to surviving tissue (see how mesenchymal stem cells really work). The more healthy tissue remains, the more those signals have to work with.
- Signals need a target. If a joint, nerve pathway or organ has lost most of its cells, there is little left to protect or stimulate.
- Some losses are hard to reverse. Nerve cells in the brain and spinal cord regenerate poorly, and cartilage that has worn down to bone cannot simply regrow. Slowing damage is a more realistic aim than undoing it. Read more in how stem cells can slow down disease progression.
- The biology changes over time. A 2020 review of spinal cord injury trials notes that injury moves through acute, subacute and chronic damage, so the environment a cell therapy meets depends on when it is given.
- Overall health matters. Later in a disease, other problems (weight loss, infections, heart or lung limits) can reduce how safely a person can travel and be treated.
Earlier is a sensible biological expectation, but for most conditions no trial has proven an ideal window. The next section shows what the studies do and do not say.
Timing by condition: what the research shows
Only a few studies compare disease stages directly, so the honest summary is that earlier treatment looks promising in several conditions but an ideal window has not been proven for any of them. The table lists what published studies reported.
| Condition | What the research reported about timing | Evidence caveat |
|---|---|---|
| Knee osteoarthritis | A systematic review of 12 studies (539 patients) found single injections of a patient’s own minimally processed cells safe and effective for Kellgren-Lawrence grades I to III. One study found bigger gains in grade 2 than grade 3. | Only two studies split results by grade, so the review does not prove earlier grades do better. Grade IV was not covered. |
| Multiple sclerosis | In a Mexican centre study of 74 patients followed 3 years or more, those with no earlier disease-modifying drugs did better. Median EDSS went from 4.5 to 4, versus 5.5 unchanged. | Small and variable; disease length was not measured directly. This studied blood stem cell transplant (aHSCT), not mesenchymal cell injections. |
| ALS | In the NurOwn phase 3 trial (189 patients), 34.7% of treated and 27.7% of placebo patients progressed more slowly, which was not significant. In people with a starting ALSFRS-R of 35 or more, it was 34.6% versus 15.6%. | The earlier-stage result was a company subgroup analysis, not the main finding. The trial’s main goal was missed. |
| Parkinson’s disease | The STEM-PD trial (Nature Medicine, 9 July 2026) put dopamine cell precursors into the brains of 8 patients. Seven finished 12 months, were stable, and six cut their medication. | Tiny, open-label, aimed at safety. It does not say which stage benefits most. |
| Spinal cord injury | A 2020 review found no agreed best time. One trial saw ASIA improvement in 30% of patients treated within 8 weeks and 0% after 8 weeks. Most trials treat chronic injuries. | Trials differ in cell type, dose and route, and some patients recover on their own early on. |
For cerebral palsy, retinitis pigmentosa, avascular necrosis, stroke and diabetes, staging and expected outcomes are on their own pages: cerebral palsy, retinitis pigmentosa, avascular necrosis, stroke and diabetes.
Is it ever too late for stem cell therapy?
Late-stage disease rarely means there are no options, but it changes the goals, the safety review and the outcomes you can reasonably expect.
- Goals shift. In advanced disease, realistic aims to discuss with a doctor are slowing further decline, easing symptoms and supporting rehabilitation, not full recovery.
- Safety comes first. Frailty, active infection, uncontrolled heart, lung or kidney problems, or an inability to travel can make treatment unsafe. See who is eligible for stem cell therapy and the limits of stem cell therapy.
- Age is not the cutoff. Overall health matters more than the number; the guide for elderly patients explains what is assessed.
- An honest provider will say no. If the expected benefit at your stage is minimal, a responsible team tells you so rather than offering hope it cannot support.
If you are told you are too late by one clinic, a second opinion is reasonable. You can request one through Viezec’s expert opinion service.
Factors beyond stage that affect timing
Stage is only one input. Doctors also weigh:
- Speed of progression. A condition that worsens quickly gives you a shorter window than one that has been stable for years.
- Cause of the condition. Autoimmune, degenerative and injury-related conditions behave differently, so the logic for timing differs.
- Overall health and age. Other illnesses affect safety and recovery. See the elderly patient guide.
- Earlier treatments. What has already been tried, and what response you had, shapes the plan. In the multiple sclerosis study above, people who had not used earlier drugs fared better.
- Cell source and delivery. Cells from bone marrow, fat or cord tissue behave differently. Compare the different sources of stem cells.
- Rehabilitation and lifestyle. Therapy and nutrition after treatment affect results. See nutrition and lifestyle for better outcomes and what to expect after a stem cell injection.
What the evidence says, and what it does not
The evidence supports caution about any firm claim on timing, for four reasons.
- Studies are small and varied. The knee review authors point to differences in cell sources and preparation, and note that most outcomes were short term.
- Some large trials missed their goals. The NurOwn ALS phase 3 trial did not meet its main endpoint, and its earlier-stage result came from a later subgroup analysis.
- Early results are about safety. The STEM-PD Parkinson’s trial was small and open-label and was designed to test safety and feasibility.
- Natural recovery muddies the picture. In spinal cord injury, some patients improve on their own, so comparisons need control groups.
Outside blood disorders treated with blood stem cell transplants, most stem cell uses are still investigational. Be wary of anyone who promises a cure or guarantees that earlier treatment will work. For independent guidance, the ISSCR patient guide is written to help patients and families decide. Viezec’s own pages cover safety, the legal position and success rates.
How to decide: questions to ask and records to prepare
Bring these seven questions to any consultation, here or elsewhere:
- What is my current stage on the scale used for my condition, and what is my score?
- How fast is my condition progressing?
- What does published evidence say for someone at my stage?
- What is a realistic goal for me: recovery, slowing, or symptom relief?
- What are the risks, and who is not a suitable candidate?
- What changes if I wait six to twelve months?
- Are there approved treatments I should start or continue alongside this?
Do not stop prescribed medicines on your own while you decide. Ask your treating doctor first.
Records worth gathering:
- Recent MRI, CT or X-ray reports and images
- Latest scores from your scale (EDSS, ALSFRS-R, Hoehn and Yahr, KL grade or similar)
- A list of current medicines and past treatments with dates
- Recent blood test results and discharge summaries
- A short phone video of daily movement or walking, if relevant
You can send these for review through expert opinion or book a live tele-consultation. If you plan to travel, read the patient guide and treatment timeline.
Frequently asked questions
It is often expected to be, because more healthy tissue is left for repair signals to act on. However, few studies compare stages directly, so early treatment is a reasonable expectation, not a proven rule. Your own stage and speed of progression decide what is realistic.
Studies have mainly treated Kellgren-Lawrence grades I to III, where some cartilage remains. A 2023 review found benefit across those grades, with one study showing bigger gains in grade 2 than grade 3. Bone-on-bone (grade IV) disease was not covered, and surgery is often discussed.
Sometimes the goal can still be slowing decline or easing symptoms, but full recovery is unlikely. Late stage also raises safety questions, such as frailty or infection. A specialist should review your records before any promise is made.
Waiting can mean losing function in a progressive condition, while rushing can mean unproven treatment. Discuss the risk of both with your doctor, keep any proven treatment going, and get a second opinion if you are unsure.
Your doctor scores it on a scale for your condition, such as KL grade for the knee, EDSS for multiple sclerosis, ALSFRS-R for ALS or Hoehn and Yahr for Parkinson’s. Ask for the number and the date it was measured.
Age alone is not the cutoff. Overall health, other illnesses and fitness to travel matter more. See the elderly patient guide.
No. It is usually discussed alongside, not instead of, proven treatment. Never stop prescribed medicines without your treating doctor’s advice.
The bottom line
The best time to look into stem cell therapy is usually early, once your condition is confirmed and staged, and before major function is lost. That is a reasoned expectation, not a guarantee, and it should come from your own scores and scans rather than a generic rule.
If you want a view on your stage, send your reports for a second opinion, or contact Viezec.
This article is for education and is not medical advice. Decisions about treatment should be made with your treating doctor.
Conditions We Treat
Explore stem cell treatment options in India
